Liraglutide & Ketamine: Saxenda / Victoza Compatibility
Victoza (Liraglutide) (also: Saxenda) — GLP-1 receptor agonist (diabetes, weight loss)
Verdict at Tovani Health
Fully compatible with KAP; same profile as semaglutide.
Liraglutide and ketamine have no clinically significant interaction. Victoza (type 2 diabetes) and Saxenda (chronic weight management) are the same molecule at different doses; both work fine alongside KAP. Saxenda was historically the first GLP-1 receptor agonist to carry a suicidal-ideation-and-behavior warning in its FDA labeling — a class requirement for chronic weight management drugs acting on the CNS — but the January 2026 FDA review found no causal link to suicidality and formally requested removal of the warning. The interaction profile for ketamine therapy is identical to the rest of the GLP-1 class.
If you take Victoza regularly and are considering at-home ketamine therapy, the combination is generally safe at therapeutic doses. This page covers the brief pharmacologic context and what we do at intake.
How Victoza interacts with ketamine
Liraglutide is a daily-injection GLP-1 receptor agonist (vs. the weekly schedules of semaglutide and tirzepatide). It slows gastric emptying, increases insulin response, and reduces appetite. The daily dosing produces a more even day-to-day GI profile — less of the peak-and-trough pattern weekly injections create. No overlap with ketamine pharmacology: no shared NMDA receptor activity, no shared CYP metabolism (ketamine is primarily CYP3A4/CYP2B6).
What we do at intake
Continue daily injection as normal. Tell us your dose, indication (Victoza for diabetes vs Saxenda for weight loss), and whether GI side effects are an issue. If you've experienced significant mood changes on liraglutide personally, share that — even though the population-level data shows no class-wide depression signal, individual experiences matter for planning your ketamine course.
Bottom line
Liraglutide and ketamine have no clinically significant interaction. Victoza (type 2 diabetes) and Saxenda (chronic weight management) are the same molecule at different doses; both work fine alongside KAP. Saxenda was historically the first GLP-1 receptor agonist to carry a suicidal-ideation-and-behavior warning in its FDA labeling — a class requirement for chronic weight management drugs acting on the CNS — but the January 2026 FDA review found no causal link to suicidality and formally requested removal of the warning. The interaction profile for ketamine therapy is identical to the rest of the GLP-1 class.
Frequently Asked Questions
Saxenda was the first GLP-1 with a suicidal-ideation warning — does that change anything for ketamine therapy?
No. The warning was an FDA class rule for chronic weight management drugs that act on the CNS — Saxenda was the originator in 2014, and Wegovy and Zepbound inherited the same warning later. The January 2026 FDA review of 91 trials and 107,910 participants found no evidence of increased suicidality and formally requested the warning be removed from all three labels. Ketamine therapy is unaffected by this history.
I take Victoza for diabetes, not weight loss. Same compatibility as Saxenda?
Yes — identical molecule (liraglutide), just at a different dose. The compatibility profile with ketamine is the same.
Does daily injection matter differently than weekly Ozempic for session planning?
Slightly. Daily liraglutide produces a more predictable day-to-day GI profile than weekly semaglutide. Less of a peak/trough nausea pattern around dosing days. Session timing tends to be more flexible.
I'm being switched from Saxenda to Wegovy. Should I pause ketamine during the transition?
Usually not necessary. The two drugs are different molecules (liraglutide vs semaglutide) but share the same class profile. Transition-week GI symptoms can be planned around if a session falls in the same window.
Ready to find out if at-home ketamine fits your situation?
We’ll note that you’re on Victoza (Liraglutide) at intake. The eligibility check takes 5 minutes and gives you an honest answer about whether at-home ketamine fits your specific situation.
FL and NJ residents only. Benjamin Soffer, DO — Tovani Health.
Sources
The verdict and clinical guidance on this page are based on the following peer-reviewed literature and FDA prescribing information.
- FDA Requests Removal of Suicidal Ideation Warning From GLP-1 RA Medications. Voelker R.. JAMA. 2026. PMID: 41615669
January 2026 FDA action — Saxenda (liraglutide) was the originator of the SI warning on GLP-1 labels; this communication removed it.
- Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs. et al.. International Journal of Clinical Pharmacy. 2026. PMID: 41739406
Class-wide pharmacovigilance analysis including liraglutide — no signal.
- Implications of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) for Mood Disorders and Suicide Risk. et al.. Biological Psychiatry. 2026. PMID: 42069105
Comprehensive review of GLP-1 RA evidence on mood; no causal link at population level.
- Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy. Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI.. Clinical Pharmacokinetics. 2016. PMID: 27028535
Ketamine PK/PD foundational reference confirming the absence of metabolic overlap with the GLP-1 class.
Clinically reviewed
Reviewed by Benjamin Soffer, DO on May 27, 2026. Dr. Soffer is a board-certified physician (American Board of Internal Medicine) licensed in Florida and New Jersey, prescribing at-home ketamine therapy through Tovani Health.
This page is general information about how this medication interacts with at-home ketamine therapy at Tovani Health. It is not a substitute for medical advice from your prescribing physician about your specific situation. Always discuss medication changes with the doctor who prescribed them.